If you’d invested in: Indivior and Next

Drugmaker Indivior is on the up, while retailer Next, once a favourite with investors, has lost its way.

If only

Indivior (LSE: INDV) is a pharmaceutical company that specialises in producing Suboxone, a prescription drug for the treatment of patients who are dependent on opioids. The firm operates in 40 countries worldwide. It was set up in 1994 as the pharmaceuticals division of consumer goods giant Reckitt Benckiser, but was spun off in December 2014 and listed as Indivior on the London Stock Exchange.In its first year as a public company, it made an operating profit of $346m on revenue of $1bn. Over the last year, the shares have risen by more than 130%.

Be glad you didn't

Fashion retailer Next (LSE: NXT) was once a favourite with investors. Between 2008 and late 2015, its shares rose by almost ten times. But since then, the company has lost its way as retail trends change. Last year proved difficult as customers deserted the chain, leading to multiple profit warnings. There's no relief in sight: last month, the firm warned that 2017 will be even tougher. The share price has slumped by over 40% in the past year.